|
41 Companies |
|
50 Products |
|
50 Products |
|
53 Mechanisms of Action |
|
1 Trial |
|
299 News |
|
| «123456» |
- cisplatin / Generic mfg., docetaxel / Generic mfg., sorafenib / Generic mfg.
Enrollment change, Trial primary completion date, Combination therapy, Metastases: Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Jul 29, 2016
P1/2, N=3, Active, not recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
N=41 --> 3 | Trial primary completion date: Mar 2017 --> Dec 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Trial primary completion date, Surgery, Metastases: Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery (clinicaltrials.gov) - Jul 19, 2016
P2, N=76, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=41 --> 3 | Trial primary completion date: Mar 2017 --> Dec 2016 Trial primary completion date: May 2016 --> Dec 2016
- Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer (clinicaltrials.gov) - Jul 19, 2016
P2, N=29, Active, not recruiting, Sponsor: University of Washington
Trial primary completion date: May 2016 --> Dec 2016 Trial primary completion date: May 2016 --> Aug 2016
- ||||||| Trial completion: Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. (clinicaltrials.gov) - Jul 11, 2016
P3, N=1560, Completed, Sponsor: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Trial primary completion date: May 2016 --> Aug 2016 Recruiting --> Completed
- Trial completion: Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations (clinicaltrials.gov) - Jul 11, 2016
P4, N=240, Completed, Sponsor: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Recruiting --> Completed Recruiting --> Completed
- cisplatin / Generic mfg.
Trial primary completion date, Metastases: Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC (clinicaltrials.gov) - Jun 11, 2016
P1, N=3, Active, not recruiting, Sponsor: Virginia Commonwealth University
Recruiting --> Completed Trial primary completion date: Apr 2018 --> Mar 2016
- Trial suspension: Effects of Sustained Reading on the Ocular Surface (clinicaltrials.gov) - Jun 10, 2016
P=N/A, N=50, Suspended, Sponsor: University of Rochester
Trial primary completion date: Apr 2018 --> Mar 2016 Recruiting --> Suspended
- || gefitinib / Generic mfg.
Trial primary completion date, Metastases: Iressa Study in Patients With Salivary Gland Cancer (clinicaltrials.gov) - May 19, 2016
P2, N=80, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Suspended Trial primary completion date: Nov 2016 --> Nov 2017
- Enrollment change: Effects of Sustained Reading on the Ocular Surface (clinicaltrials.gov) - May 10, 2016
P=N/A, N=50, Recruiting, Sponsor: University of Rochester
Trial primary completion date: Nov 2016 --> Nov 2017 N=40 --> 50
- cisplatin / Generic mfg.
Enrollment closed, Trial primary completion date, Metastases: Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC (clinicaltrials.gov) - Apr 8, 2016
P1, N=3, Active, not recruiting, Sponsor: Virginia Commonwealth University
N=40 --> 50 Terminated --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Apr 2018
- | Trial completion, Trial primary completion date: Drug-induced Xerostomia. Evaluation of Malic Acid 1%, Salivary Mucins and Buffering Capacity (clinicaltrials.gov) - Apr 7, 2016
P2/3, N=185, Completed, Sponsor: Universidad de Granada
Terminated --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Apr 2018 Recruiting --> Completed | Trial primary completion date: Jan 2013 --> Jan 2014
- cisplatin / Generic mfg.
Trial termination, Metastases: Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC (clinicaltrials.gov) - Mar 24, 2016
P1, N=3, Terminated, Sponsor: Virginia Commonwealth University
The data analysis was futile with only 3 accruals. PI opted to terminate with IRB and withdraw FDA IND.
- | baminercept (BG 9924) / Biogen
Enrollment change, Trial termination: Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sj (clinicaltrials.gov) - Mar 23, 2016
P2, N=52, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
PI opted to terminate with IRB and withdraw FDA IND. N=72 --> 52 | Active, not recruiting --> Terminated; Expired experimental study agent, no additional supply available.
- cisplatin / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC (clinicaltrials.gov) - Mar 11, 2016
P1, N=3, Active, not recruiting, Sponsor: Virginia Commonwealth University
N=72 --> 52 | Active, not recruiting --> Terminated; Expired experimental study agent, no additional supply available. Suspended --> Active, not recruiting | N=15 --> 3 | Trial primary completion date: Jan 2017 --> Apr 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer (clinicaltrials.gov) - Mar 5, 2016
P2, N=24, Active, not recruiting, Sponsor: Fox Chase Cancer Center
Suspended --> Active, not recruiting | N=15 --> 3 | Trial primary completion date: Jan 2017 --> Apr 2016 Recruiting --> Active, not recruiting | N=43 --> 24 | Trial primary completion date: Feb 2016 --> Mar 2015
- cisplatin / Generic mfg.
Trial completion: A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors (clinicaltrials.gov) - Feb 26, 2016
P2, N=120, Completed, Sponsor: King Faisal Specialist Hospital & Research Center
Recruiting --> Active, not recruiting | N=43 --> 24 | Trial primary completion date: Feb 2016 --> Mar 2015 Recruiting --> Completed
- acetylcysteine solution / Generic mfg.
Enrollment closed, Enrollment change: Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy (clinicaltrials.gov) - Feb 5, 2016
P=N/A, N=18, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Completed Recruiting --> Active, not recruiting | N=36 --> 18
- | Phase classification, Enrollment change, Trial initiation date, Trial primary completion date: Laser Therapy to Treat the Dry Mouth of Sjogren's Syndrome (clinicaltrials.gov) - Feb 3, 2016
P3, N=72, Recruiting, Sponsor: Federal University of S
Recruiting --> Active, not recruiting | N=36 --> 18 Phase classification: P2 --> P3 | N=34 --> 72 | Initiation date: Jan 2014 --> May 2014 | Trial primary completion date: Jun 2014 --> Jun 2016
- Trial completion, Surgery: Evaluation of Safety and Effectiveness of the FMwand Ferromagnetic Surgical System During Parotidectomy Surgery (clinicaltrials.gov) - Jan 26, 2016
P=N/A, N=5, Completed, Sponsor: Domain Surgical, Inc.
Phase classification: P2 --> P3 | N=34 --> 72 | Initiation date: Jan 2014 --> May 2014 | Trial primary completion date: Jun 2014 --> Jun 2016 Active, not recruiting --> Completed
- Halaven (eribulin mesylate) / Eisai
Enrollment closed, Metastases: Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer (clinicaltrials.gov) - Jan 20, 2016
P2, N=29, Active, not recruiting, Sponsor: University of Washington
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Vectibix (panitumumab) / Amgen
Enrollment change, Trial primary completion date: Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies (clinicaltrials.gov) - Jan 11, 2016
P2, N=0, Withdrawn, Sponsor: University of Pittsburgh
Recruiting --> Active, not recruiting N=30 --> 0 | Trial primary completion date: Nov 2013 --> Aug 2011
- timbetasin ophthalmic (RGN-259) / ReGenTree
Enrollment change: Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye (clinicaltrials.gov) - Dec 23, 2015
P2, N=9, Completed, Sponsor: Michigan Cornea Consultants, PC
N=30 --> 0 | Trial primary completion date: Nov 2013 --> Aug 2011 N=18 --> 9
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
Trial completion, Trial primary completion date, Metastases: MAESTRO HN: Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy (clinicaltrials.gov) - Dec 23, 2015
P2, N=82, Completed, Sponsor: National Cancer Institute (NCI)
N=18 --> 9 Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Dec 2013
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Trial primary completion date, Surgery, Metastases: Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery (clinicaltrials.gov) - Dec 12, 2015
P2, N=76, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Dec 2013 Trial primary completion date: Dec 2015 --> May 2016
- | Enrollment closed, Trial primary completion date: Acupuncture in Treating Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer (clinicaltrials.gov) - Dec 12, 2015
P3, N=240, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2015 --> May 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2016 --> Nov 2017
- | tropicamide / Generic mfg.
Trial completion: Study of the Safety and Efficacy of Tropicamide Thin Films to Reduce Hypersalivation in Parkinson's Patients (clinicaltrials.gov) - Dec 12, 2015
P2, N=30, Completed, Sponsor: NeuroHealing Pharmaceuticals Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2016 --> Nov 2017 Active, not recruiting --> Completed
- Biomarker, Enrollment status: Salivary Biomarkers for Sj (clinicaltrials.gov) - Dec 6, 2015
P=N/A, N=420, Enrolling by invitation, Sponsor: University of California, Los Angeles
Active, not recruiting --> Completed Recruiting --> Enrolling by invitation
- Trial primary completion date: Effects of Sustained Reading on the Ocular Surface (clinicaltrials.gov) - Dec 5, 2015
P=N/A, N=40, Recruiting, Sponsor: University of Rochester
Recruiting --> Enrolling by invitation Trial primary completion date: Apr 2016 --> Dec 2016
- Enrollment change, Trial withdrawal: Development of a Milk Product Substitution for Patients Suffering From Xerostomia Caused by Medication (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=0, Withdrawn, Sponsor: Institut National de la Sant
Trial primary completion date: Apr 2016 --> Dec 2016 N=32 --> 0 | Recruiting --> Withdrawn
- ||||||| Priorix (MMR vaccine) / GSK
Trial completion: Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older (clinicaltrials.gov) - Nov 25, 2015
P3, N=1000, Completed, Sponsor: GlaxoSmithKline
N=32 --> 0 | Recruiting --> Withdrawn Active, not recruiting --> Completed
- ||||||| M-M-RII (measles, mumps, and rubella virus vaccine live) / Merck (MSD)
Trial completion: A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED) (clinicaltrials.gov) - Oct 22, 2015
P3, N=1997, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed No longer recruiting --> Completed
- | tropicamide / Generic mfg.
Trial completion: NH004-2: Safety and Efficacy Study of NH004 Films for Relief of Sialorrhea Symptoms in Parkinson's Disease Patients (clinicaltrials.gov) - Oct 13, 2015
P2, N=19, Completed, Sponsor: NeuroHealing Pharmaceuticals Inc.
No longer recruiting --> Completed Recruiting --> Completed
- NN1213 / Novo Nordisk
Enrollment change, Trial termination: Evaluation of Salivary Gland Dysfunction (clinicaltrials.gov) - Oct 1, 2015
P=N/A, N=1740, Terminated, Sponsor: National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting --> Completed N=99999999 --> 1740 | Recruiting --> Terminated
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Sep 30, 2015
P1, N=43, Completed, Sponsor: National Cancer Institute (NCI)
N=99999999 --> 1740 | Recruiting --> Terminated Active, not recruiting --> Completed
- Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer (clinicaltrials.gov) - Sep 24, 2015
P2, N=29, Recruiting, Sponsor: University of Washington
Active, not recruiting --> Completed Trial primary completion date: Nov 2015 --> May 2016
- Enrollment closed, Trial primary completion date: Multi-Colored Placido Disk Viability (clinicaltrials.gov) - Sep 22, 2015
P=N/A, N=20, Active, not recruiting, Sponsor: University of Rochester
Trial primary completion date: Nov 2015 --> May 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Sep 2016
- | dovitinib (TKI258) / Novartis, Oncoheroes
Trial completion, Metastases: DOVE: A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands (clinicaltrials.gov) - Sep 17, 2015
P2, N=21, Completed, Sponsor: Ontario Clinical Oncology Group (OCOG)
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Sep 2016 Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer (clinicaltrials.gov) - Sep 8, 2015
P2, N=43, Recruiting, Sponsor: Fox Chase Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Feb 2015 --> Feb 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Enrollment change, IO biomarker, Metastases: Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab (clinicaltrials.gov) - Sep 1, 2015
P2, N=55, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Feb 2015 --> Feb 2016 Active, not recruiting --> Completed | N=88 --> 55
- ||||| Xeomin (incobotulinumtoxinA) / Merz Pharma
Enrollment closed: SIAXI: Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions (clinicaltrials.gov) - Aug 27, 2015
P3, N=180, Active, not recruiting, Sponsor: Merz Pharmaceuticals GmbH
Active, not recruiting --> Completed | N=88 --> 55 Recruiting --> Active, not recruiting
- |||| Xeomin (incobotulinumtoxinA) / Merz Pharma
Trial primary completion date: SIAXI: Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions (clinicaltrials.gov) - Aug 21, 2015
P3, N=180, Recruiting, Sponsor: Merz Pharmaceuticals GmbH
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2015 --> Dec 2015
- Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Trial completion, Enrollment change, Trial primary completion date: ALS-TOX: Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea (clinicaltrials.gov) - Aug 14, 2015
P2, N=18, Completed, Sponsor: Hospices Civils de Lyon
Trial primary completion date: Jul 2015 --> Dec 2015 Recruiting --> Completed | N=90 --> 18 | Trial primary completion date: Aug 2015 --> Mar 2014
- sunitinib / Generic mfg.
Trial completion, Enrollment change, Metastases: A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands (clinicaltrials.gov) - Aug 12, 2015
P2, N=14, Completed, Sponsor: University Health Network, Toronto
Recruiting --> Completed | N=90 --> 18 | Trial primary completion date: Aug 2015 --> Mar 2014 Active, not recruiting --> Completed | N=25 --> 14
- Xeomin (incobotulinumtoxinA) / Merz Pharma
Enrollment change, Trial withdrawal: Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Aug 12, 2015
P2, N=0, Withdrawn, Sponsor: Beth Israel Deaconess Medical Center
Active, not recruiting --> Completed | N=25 --> 14 N=20 --> 0 | Recruiting --> Withdrawn
- cyclosporin A microemulsion / Generic mfg.
Trial completion: CYPRESS: Low Dose Cyclosporin A in Primary Sj (clinicaltrials.gov) - Aug 12, 2015
P2, N=30, Completed, Sponsor: Charite University, Berlin, Germany
N=20 --> 0 | Recruiting --> Withdrawn Active, not recruiting --> Completed
- | tropicamide / Generic mfg.
Enrollment closed, Trial primary completion date: Study of the Safety and Efficacy of Tropicamide Thin Films to Reduce Hypersalivation in Parkinson's Patients (clinicaltrials.gov) - Aug 11, 2015
P2, N=36, Active, not recruiting, Sponsor: NeuroHealing Pharmaceuticals Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Oct 2015
- Enrollment closed, Surgery: Evaluation of Safety and Effectiveness of the FMwand Ferromagnetic Surgical System During Parotidectomy Surgery (clinicaltrials.gov) - Aug 11, 2015
P=N/A, N=5, Active, not recruiting, Sponsor: Domain Surgical, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Oct 2015 Recruiting --> Active, not recruiting
- | prezalumab (AMG 557) / Amgen, AstraZeneca
Enrollment open: A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sj (clinicaltrials.gov) - Aug 3, 2015
P2, N=42, Recruiting, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Trial primary completion date: A Study of Flt3-Ligand Levels in Sj (clinicaltrials.gov) - Jul 9, 2015
P=N/A, N=50, Recruiting, Sponsor: G
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2015 --> Jun 2016
- acetylcysteine solution / Generic mfg.
Trial primary completion date: Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy (clinicaltrials.gov) - Jun 25, 2015
P=N/A, N=36, Recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Jun 2015 --> Jun 2016 Trial primary completion date: Apr 2015 --> Apr 2018